The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane

Abstract

Strategies for the development of anticancer drug delivery systems have undergone a dramatic transformation in the last few decades. Lipid-based drug delivery systems, such as a nanostructured lipid carrier (NLC), are one of the systems emerging to improve the outcomes of tumor treatments. However, NLC can act as an intruder and cause an immune response. To overcome this limitation, biomimicry technology was introduced to decorate the surface of the nanoparticles with various cell membrane proteins. Here, we designed paclitaxel (PT)-loaded nanostructured lipid carrier (PT-NLC) with platelet (PLT) membrane protein because PLT is involved with angiogenesis and interaction of circulating tumor cells. After PLT was isolated from blood using the gravity-gradient method and it was used for coating PT-NLC. Spherical PT-NLC and platelet membrane coated PT-NLC (P-PT-NLC) were successfully fabricated with high encapsulation efficiency (EE) (99.98%) and small particle size (less than 200 nm). The successful coating of PT-NLC with a PLT membrane was confirmed by the identification of CD41 based on transmission electron microscopy (TEM), western blot assay and enzyme-linked immunosorbent assay (ELISA) data. Moreover, the stronger affinity of P-PT-NLC than that of PT-NLC toward tumor cells was observed. In vitro cell study, the PLT coated nanoparticles successfully displayed the anti-tumor effect to SK-OV-3 cells. In summary, the biomimicry carrier system P-PT-NLC has an affinity and targeting ability for tumor cells.

Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review

“…Coating with PLT is an approach usually used to decrease the immune response occurring after administration of drug-loaded lipid-based NPs [95]. This approach also increased the affinity and targeting ability of the drug-loaded NLCs than that of the uncoated NPs toward SKOV3 ovarian cancer cell and maintained the ability of the NLCs to prolong the release of PTX as well [96].…”

Development and Evaluation of Docetaxel-Phospholipid Complex Loaded Self-Microemulsifying Drug Delivery System: Optimization and In Vitro/Ex Vivo Studies

“…The large surface area by nanosized droplets can promote the contact between the drug and the cell membrane, thereby enhancing the cellular uptake of drug. In addition, the synergistic effects of phospholipids and lipophilic excipients can improve drug absorption by improving affinity for the cell membranes [ 18 ]. Hence, these results supported that the dual technique can overcome the low GI permeation of DTX.…”

“…The mixture was shaken for 10 min to obtain a homogenous microemulsion. The degree of self-emulsification was evaluated in terms of three-standards, including droplet size, transmittance, and phase separation, based on the previously reported grading system ( Table 1 ) [ 18 ]. Droplet size (diameter) was measured using an electrophoretic laser scattering (ELS) analyzer (ELS-Z2; Otsuka Electronics, Osaka, Japan) at 25 °C after diluting the formulation (100 mg) with distilled water (10 mL).…”

Cancer Nanomedicine

“…Within this Special Issue, a diverse range of cancer nanomedicines have been discussed, including the more traditional organic-based systems, such as lipid [ 1 , 2 , 3 , 4 , 5 , 6 ], polymer [ 7 , 8 , 9 , 10 , 11 ] and cyclodextrin-based [ 12 ] particulates. Additionally, there are multiple studies from the growing area of inorganic systems, such as carbon nanomaterials (such as graphene oxide [ 13 , 14 ] and carbon nanotubes [ 15 ]) as well as other more established metallic nanomaterials, such as gold [ 16 , 17 ], iron oxide [ 18 , 19 ] and silica-based [ 20 , 21 ] systems.…”

“…As the science develops and leads us down new avenues, the findings and their meaning are closely scrutinised and debated within the community. This issue includes 32 scientific manuscripts, 13 review articles and 1 case report reflecting the hot topics within this area [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ].…”